The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Open accessAbstract
Importance: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti-epidermal growth factor receptor-based regimen might be efficacious. Recent data suggest the role of liquid biopsy as a tool to track molecular events in circulating tumor DNA (ctDNA). Objective: To prospectively assess the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type mCRC who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy. Design, Setting, and Participants: Multicenter phase 2 single-arm trial conducted from January 7, 2015, to June 19, 2017. Liquid biopsies for analysis of ctDNA were collected at baseline. Main eligibility criteria included RAS and BRAF wild-type status on tissue samples; prior first-line irinotecan- and cetuximab-based regimen with at least partial response, progression-free survival of at least 6 months with first-line therapy, and progression within 4 weeks after last dose of cetuximab; and prior second-line oxaliplatin- and bevacizumab-based treatment. Interventions: Biweekly cetuximab, 500 mg/m2, plus irinotecan, 180 mg/m2. Main Outcomes and Measures: Overall response rate according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival and overall survival and, as an exploratory analysis, RAS mutations in ctDNA. Results: Twenty-eight patients (9 women and 19 men; median age, 69 years [range, 45-79 years]) were enrolled. Six partial responses (4 confirmed) and 9 disease stabilizations were reported (response rate, 21%; 95% CI, 10%-40%; disease control rate, 54%; 95% CI, 36%-70%). Primary end point was met because lower limit of 95% CI of response rate was higher than 5%. RAS mutations were found in ctDNA collected at rechallenge baseline in 12 of 25 evaluable patients (48%). No RAS mutations were detected in samples from patients who achieved confirmed partial response. Patients with RAS wild-type ctDNA had significantly longer progression-free survival than those with RAS mutated ctDNA (median progression-free survival, 4.0 vs 1.9 months; hazard ratio, 0.44; 95% CI, 0.18-0.98; P = .03). Conclusions and Relevance: This is the first prospective demonstration that a rechallenge strategy with cetuximab and irinotecan may be active in patients with RAS and BRAF wild-type mCRC with acquired resistance to first-line irinotecan- and cetuximab-based therapy. The evaluation of RAS mutational status on ctDNA might be helpful in selecting candidate patients. Trial Registration: ClinicalTrials.gov Identifier: NCT02296203.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BRAF mutation is a powerful biomarker of poor prognosis for mCRC patients receiving anti-EGFR mAbs [80, 91, 92].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“Objective response ratea (95% CI) 6 (21) (10-40)”
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citationCOSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
Research works printed but not linked: 3
- Meazza, 2016, AKT1 and BRAF mutations in pediatric aggressive fibromatosis., Cancer Med, 5, 1204, 10.1002/cam4.2016.5.issue-6 · DOI
- dbSNP: short genetic variations. Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. https://www.ncbi.nlm.nih.gov/SNP/. Accessed June 15, 2018.
- ClinVar. https://www.ncbi.nlm.nih.gov/clinvar/. Accessed June 15, 2018.
Cited by
Sorted by citations
Items 401–426 of 426
Predictive biomarkers in clinical practice in colorectal cancer
Rodríguez-Castells, M., & Élez, E. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00131
Boige, V., Bouché, O., Mulot, C., Evesque, L., Abdelghani, M. B., Phelip, J., Mineur, L., Galais, M., Villing, A.-L., Hautefeuille, V., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3555
Biología molecular del cáncer colorrectal
García‐Foncillas, J., Jiménez, P., Ávila-Rodríguez, V., Macías, S. I. G., Manrique, M. E., Rendón-Hernández, J., Angarita, J. M., Calvo, J. F., & Bonilla, C. E. (2026) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.853
Marko, M., Kukic, B. P., Kolarov-Bjelobrk, I., Nemanja, P., Aleksandar, D., Novak, S., & Urosevic, T. (2025) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2025.02.03
Effect of sex differences on the emergence of ctDNA RAS mutations in RAS wild-type colorectal cancer
Iguchi, K., UCHIYAMA, M., Asari, M., Numata, K., & Shiozawa, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-42920-2
Kuzmina, E. S., Fedyanin, M. Y., Feoktistova, P. S., Lyadova, M. A., Fedorinov, D. S., Magamedova, O. R., Parts, S., Polyanskiy, M. A., Fekhtel, E., Покатаев, И. А., et al. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2026.1.203557
Burge, M., Tie, J., Krishnan, T., Roy, A., Chantrill, L., Tebbutt, N. C., Karapetis, C. S., & Price, T. J. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.04.001
Choice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer
Naydin, G., Makiev, G. G., Barsova, D. A., Moiseenko, F. V., Rays, A., Fedyanin, M. Y., Петровна, Ч. А., Evdokimov, V. I., Zhukova, L. G., Stroyakovsky, D. L., et al. (2026) · Malignant tumours · doi:10.18027/2224-5057-2026-072
Circulating tumour DNA in colorectal cancer: current and emerging clinical applications
O’Rourke, H., & Tie, J. (2026) · Academia oncology. · doi:10.20935/acadonco8279
Liquid Biopsy and Circulating Biomarkers
Russo, T. D. B., Gristina, V., Pepe, F., Incorvaia, L., Galvano, A., Bazan, V., Malapelle, U., Giordano, A., & Russo, A. D. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_19
Sunakawa, Y., Yasui, H., Shiozawa, M., Takeda, H., Akazawa, N., Sagawa, T., Shiraishi, K., Kyogoku, T., Mine, T., Yuasa, Y., et al. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01223-2
Einsatzmöglichkeiten und Grenzen der Liquid Biopsy
Bonzheim, I. (2026) · Die Pathologie · doi:10.1007/s00292-026-01568-5
Yamada, T., Nagasaka, T., Matsuhashi, N., Takahashi, T., Hirata, K., Nakamura, Y., Sugimoto, K., Koda, K., Hiramatsu, K., Matsuoka, H., et al. (2026) · Cancers · doi:10.3390/cancers18111688
Liu, C., & Wang, Y. (2026) · International Journal of Surgical Pathology · doi:10.1177/10668969261457880
Hou, H., Liu, P., Dong, X., Gai, W., Jiang, P., Yang, F., & 郝崇礼 (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1833355
Miyashita, Y., Kagawa, Y., Watanabe, J., Suwa, Y., Kato, T., Hasegawa, H., Komatsu, Y., Yuki, S., Asayama, M., Nishina, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9883234/v1
Nakajo, M., Hirahara, D., Baba, K., Hirahara, M., Eizuru, Y., Tani, A., Takumi, K., Kamimura, K., Kanzaki, F., Ohtsuka, T., et al. (2026) · British Journal of Radiology · doi:10.1093/bjr/tqag129
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01524-9
Chang, P., Hsieh, M., Teng, H., Liang, Y.-H., Chen, H.-H., Hsu, H., Jiang, J., Chiang, F., Lin, J. Y., Lin, B., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261457553
Chen, H. Z., Jiang, T., Wang, H., zheng, J., Du, B., Weng, X., Yao, N., Zhu, Y., Liu, Q., Lin, F., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16491-4
Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117112
Liquid biopsy in colorectal cancer: redefining surgical decision-making
Rausa, E., Grandis, M. C. D., Bergamo, F., Aiolfi, A., & Vitellaro, M. (2026) · Updates in Surgery · doi:10.1007/s13304-026-02823-3
Self-citationYaringaño, J., Pastor, P. G., Salvà, F., Gonzalez, N. S., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., Baselga, P. M., García, A., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00199
Wang, D., Chen, W. C., Ren, C., Wang, F., Wang, Z., Luo, H., Wang, F., Tan, Q., & Li, Y. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70827
S3-Leitlinie Kolorektales Karzinom
Pox, C. P., Reichermeier, S., Aretz, S., Graeven, U., Hüneburg, R., Hüppe, D., Koch, C., Köhne, C.-H., Kolligs, F. T., Ludwig, L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2853-0320
Metadata
- Authors
- Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., Tamburini, E., Barone, C., Masi, G., Pantano, F., Pucci, F., Corsi, D. C., Pella, N., Bergamo, F., Rofi, E., Barbara, C., Falcone, A., & Santini, D.
- Affiliations
- University of Pisa (IT)
- Università Campus Bio-Medico (IT)
- Istituto Oncologico Veneto (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, Pisa, Italy
- University of Udine (IT)
- Ospedale Infermi di Rimini (IT)
- Università Cattolica del Sacro Cuore (IT)
- Ospedale di Parma (IT)
- Fatebenefratelli Hospital (IT)
- Medical Oncology Unit, Presidio Ospedaliero Felice Lotti, Pontedera, Italy
- Corresponding author
- Falcone, Alfredo
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-03-01
- Volume
- 5
- Issue
- 3
- Pages
- 343
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6439839
- OpenAlex
- W2901178367
- Cited by
- 424
- References
- 38
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 75 · 2023: 66 · 2022: 72 · 2021: 61 · 2020: 47 · 2019: 18
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Merck KGaA
- Eisai
- Università Cattolica del Sacro Cuore
- Servier
- Ipsen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, cetuximab, irinotecan, drug rechallenge, RAS wild-type, BRAF wild-type, acquired resistance, anti-EGFR therapy, circulating tumor DNA, liquid biopsy, third-line therapy, oxaliplatin, bevacizumab, RAS mutations, progression-free survival, overall survival, response rate, disease control rate, predictive biomarkers
- MeSH terms
- Cetuximab, Irinotecan, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Italy, Male, Middle Aged, Prospective Studies, Genes, ras, Risk Factors, Time Factors, Biomarkers, Tumor, Colorectal Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
